Autologous stem cell transplantation (ASCT) has been described since 1997 as a treatment for children with polyarticular or systemic juvenile idiopathic arthritis (JIA) resistant to conventional treatment and anti-tumor necrosis factor-a agents. 1, 2 In 1999, we observed three patients with systemic JIA who died shortly after ASCT owing to macrophage activation syndrome (MAS) induced by infections. In 2003, after initial evaluation of clinical outcomes, we amended the transplantation protocol by replacing low-dose total body irradiation with fludarabine to decrease long-term side effects. 2 Subsequently, three of the first four patients developed MAS during or shortly after the conditioning. Here, we describe these three patients.
The conditioning regime consisted of anti-thymocyte globulin (ATG-Genzyme 5 mg/kg) on days À9 until À6 before transplantation, cyclophosphamide (CY, total dose 120 mg/kg) on days À7 and -6 in the first patient and on days À3 and À2 in the second patient and fludarabine (total dose 150 mg/m 2 ) on days À5 until À1 in the first patient and on days À8 until À4 in the second. The third patient started with fludarabine (at days À14 until À10), but further conditioning with ATG and CY was interrupted for 5 days as MAS occurred.
Stem cells were obtained from unprimed marrow (n ¼ 2) or peripheral blood (patient 3) after mobilization with CY and G-CSF, yielding a final product of 1.7-1.9 Â 10 6 CD34 þ cells/kg containing 1.0-5.0 Â 10 5 CD3 þ cells/kg. Neutrophil recovery (40.5 Â 10 9 /l) occurred between days 14 and 30 post-ASCT. MAS was diagnosed either clinically or histologically, according to established criteria. 3 Parameters of MAS in the course of the transplantations are described in Table 1 .
The first patient is a 13-year-old girl, with systemic JIA since she was 7 years. She developed acute fever, lethargy and abdominal pain 2 weeks after the start of the conditioning. Laboratory results (Table 1) were compatible with MAS, which was histologically confirmed by bone marrow aspiration. Treatment was started with pulsed methylprednisolone (30 mg/kg/day) and cyclosporin A (CsA) and remission of MAS was induced within a week. Viral and bacteria cultures and PCR could not identify an infectious trigger for MAS. She responded well to therapy, and steroids were tapered. Two months after transplantation, she suffered from a CMV reactivation, which was treated with valaciclovir. At that time, she showed a granulopenia, fever and rise in ferritine and triglycerids, but did not fulfill criteria for MAS. She is now 24 months after SCT and doing well without active arthritis.
The second patient, a girl with systemic JIA since the age of 6 years, underwent ASCT at the age of 11 years. She showed active joints and raised inflammatory markers at time of ASCT. To decrease the risk of MAS during the transplantation, prednisolone was maintained (1 mg/kg/ day). Before transplantation, her bronchoalveolar fluid was CMV-positive (PCR). Although she did not have symptoms of a lung infection, ganciclovir was started preemptively. During conditioning, she had three febrile reactions with tachypnoea, a rise in ferritin and fall in platelet count on day À9 (after the first dose of ATG but before start of fludarabine), day À6 (after the fourth dose of ATG and third dose of fludarabine) and day À2 (after the second dose of cyclophosphamide), all responding well to methylprednisolone (30 mg/kg). At the time of engraftment, her CMV PCR became positive in blood and she developed pneumonitis on day þ 13 in association with features of MAS (Table 1) . Bone marrow aspirate was not performed and MAS was diagnosed on clinical grounds. Ganciclovir was changed to foscarnet and she was given pulsed methylprednisolone (30 mg/kg/day for 3 days) and infliximab (10 mg/kg). She responded well and steroids were tapered without relapsing of MAS. Now she is in full remission of systemic JIA at follow-up of 2 years.
The third patient, a 10-year-old boy with systemic JIA since the age of 2 years, developed acute fever, hepatomegaly, a rash and elevated triglycerides and ferritin 4 days after the start of fludarabine. No biopsies were taken and MAS was diagnosed on clinical grounds (Table 1) . Fludarabine was stopped and CY and ATG were postponed for 5 days. Viral and bacterial cultures and PCR tested negative for infectious agents. Treatment for MAS was started with pulsed methylprednisolone (20 mg/ kg/day) and CsA, which induced remission within a week. After this, the conditioning was resumed. One month after SCT, he again developed fever, hepatomegaly, splenomegaly and pancytopenia and fulfilled the clinical and histological (bone marrow) criteria for a second episode of MAS. This time, MAS was associated with viral infections (adenovirus in stools, respiratory syncitial virus in nasopharyngeal aspirate and polyoma virus in urine). He responded well to steroids again. Currently, after 18 months of follow-up, he is still receiving CsA and is doing well without arthritis.
Patients with systemic JIA are known to be predisposed for MAS. 4, 5 The current ASCT protocol therefore excludes patients with active systemic features at the time of transplantation. 2 Despite these strict criteria, we describe the occurrence of four episodes of MAS in three patients after having changed the conditioning into a fludarabinebased regimen. This raises questions about the use of fludarabine in the conditioning of these specific patients. So far, no reports have been published of hemophagocytosis or MAS associated with the use of fludarabine, although one case report describes fulminant bone marrow necrosis in a patient with non-Hodgkin's lymphoma treated with fludarabine. 6 However, although not fulfilling all criteria, patient 2 showed already features of MAS before the start of fludarabine. Moreover, patient 2 showed evidence of a viral infection (CMV) at the time of diagnosis of MAS. The second episode of MAS in patient 3 seems to be triggered by viral infections as well and viral infections are a known trigger of MAS. 7 Patients with systemic JIA can react to a variety of drugs, such as sulphasalazine, gold, MTX, etanercept and anakinra with features of MAS. 8, 9 After careful evaluation of described patients, we think that MAS in systemic JIA occurs more in a disease-specific than in a drug-specific (fludarabine) fashion. Systemic JIA patients show decreased cytotoxic function. 4, 5 Moreover, MAS patients appear to have a diminished ability to control some infections. 3, 7 It can be hypothesized that defective NK cells and cytotoxic T lymphocytes fail to kill virus-infected cells and thus, to remove the source of antigenic stimulation. Such persistent antigen stimulation leads to persistent activation and proliferation of T cells associated with escalating production of cytokines that stimulate macrophages, eventually causing MAS. 10 Fludarabin, as a cytotoxic drug, may cause additional injury to lymphocytes.
As especially CsA and corticosteroids have been shown to be effective in treating MAS in systemic JIA, we recommend fludarabine to be given after the start of CsA and steroid prophylaxis.
In conclusion, in our three patients, fludarabine probably acts as a nonspecific trigger in a patient group that is predisposed for MAS. To minimize the risk for MAS in these patients, we made minor adjustments to the fludarabine regimen and will closely monitor forthcoming transplantations. Table 1 Clinical and laboratorium results in three patients with systemic JIA before and after SCT 
